Aria CV, Inc., a company dedicated to improving the lives of patients suffering from pulmonary hypertension, has secured $1.4M in a seed funding round. The capital infusion marks a significant step for the medical device startup as it works to advance its solutions.
The company's focus is on a debilitating disease that affects the arteries in the lungs and the right side of the heart, leading to high blood pressure in the lungs. Aria CV aims to develop innovative approaches to manage and potentially mitigate the severe impact of pulmonary hypertension on patients.
